Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene Polymorphisms and Atomoxetine Response in ADHD
NCT01339286Phase 4Unknown
- Sponsor
- Peking University
- Start
- Mar 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Peking University. Primary endpoint: ADHD Rating Scale IV (Investigator Rated) at 8 weeks. Status: unknown.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01339286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01339286.